NATCO Pharma Limited

NSEI:NATCOPHARM Rapporto sulle azioni

Cap. di mercato: ₹246.2b

NATCO Pharma Gestione

Gestione criteri di controllo 1/4

NATCO Pharma Il CEO è Rajeev Nannapaneni, nominato in Jun2012, ha un mandato di 12.42 anni. possiede direttamente 0.63% delle azioni della società, per un valore di ₹ 1.55B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.8 anni e 1.4 anni.

Informazioni chiave

Rajeev Nannapaneni

Amministratore delegato

₹98.7m

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO12.4yrs
Proprietà del CEO0.6%
Durata media del management7.8yrs
Durata media del Consiglio di amministrazione1.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50

Nov 18
NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 15
Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease

Oct 13
We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

Aug 13
NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

Jul 15
If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Jun 30
NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Jun 14
NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 30
NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

May 09
Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Apr 03
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Feb 21
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18
NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17
NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12
Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12
NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20
NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Dec 20
Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12
NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 23
Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

Jun 02
Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

AMMINISTRATORE DELEGATO

Rajeev Nannapaneni (47 yo)

12.4yrs

Mandato

₹98,670,000

Compensazione

Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Venkaiah Nannapaneni
MD & Chairman43.2yrs₹100.77m25.1%
₹ 61.8b
Rajeev Nannapaneni
CEO & Vice Chairman12.4yrs₹98.67m0.63%
₹ 1.6b
S. V. V. Appa Rao
Chief Financial Officer8.8yrs₹13.36mNessun dato
Donthineni Rao
President of Technical Affairs & Whole Time Directorno data₹33.69m0.030%
₹ 74.5m
Chekuri Ramesh
Company Secretary & Compliance Officer2.6yrs₹2.61mNessun dato
Potluri Prasad
Executive VP of Corporate Engineering Services & Whole Time Directorno data₹20.16m0.023%
₹ 56.6m
Pavan Bhat
Executive VP of Technical Operations & Director7.8yrs₹32.12m0.013%
₹ 32.0m
Nadella Rao
VP & Head of Operationsno dataNessun datoNessun dato
N. Rao
Executive Vice President of Corporate Affairsno dataNessun datoNessun dato
James Rajakumar
Vice President of Marketing & Sales - Domesticless than a yearNessun datoNessun dato
A. Lakshminarayana
Senior Vice President of HR & Organisational Developmentno dataNessun dato0.0062%
₹ 15.3m
M. Reddy
Executive Vice President of R&D30.6yrsNessun dato0.025%
₹ 60.6m

7.8yrs

Durata media

65yo

Età media

Gestione esperta: Il team dirigenziale di NATCOPHARM è esperto e expertise (durata media dell'incarico 7.8 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Venkaiah Nannapaneni
MD & Chairman43.2yrs₹100.77m25.1%
₹ 61.8b
Rajeev Nannapaneni
CEO & Vice Chairman19yrs₹98.67m0.63%
₹ 1.6b
Donthineni Rao
President of Technical Affairs & Whole Time Director9.8yrs₹33.69m0.030%
₹ 74.5m
Potluri Prasad
Executive VP of Corporate Engineering Services & Whole Time Director10yrs₹20.16m0.023%
₹ 56.6m
Pavan Bhat
Executive VP of Technical Operations & Director2.3yrs₹32.12m0.013%
₹ 32.0m
Agnihotra Dakshina Chavali
Independent Directorless than a yearNessun datoNessun dato
Dronadula Bhaskar
Independent Directorless than a yearNessun datoNessun dato
Lakshminarayana Bolisetty
Independent Non-Executive Directorless than a yearNessun datoNessun dato
Kantipudi Suma
Independent Non-Executive Directorless than a yearNessun datoNessun dato
Nitin Jain
Independent Non-Executive Directorless than a yearNessun datoNessun dato

1.4yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di NATCOPHARM non è considerato esperto (durata media del mandato 1.4 anni), il che suggerisce un nuovo consiglio.